DelveInsight’s “Diabetic Macular Edema Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Diabetic Macular Edema pipeline landscapes.
The report comprises Diabetic Macular Edema pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Diabetic Macular Edema therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Diabetic Macular Edema pipeline products.
Diabetic Macular Edema Overview
Diabetic Macular Edema (DME) is triggered by Diabetic Retinopathy (DR), a well-known complication of diabetes. DR is the most prevalent diabetic eye disease and the leading cause of irreversible blindness in people in their working years in developed and other developing countries.
Some of the key takeaways from the Diabetic Macular Edema Pipeline Report:
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Graybug Vision, Ocuphire Pharma, Oxurion, Unity Biotechnology, etc., are developing therapies for the treatment of Diabetic Macular Edema.
-
Emerging therapies such as Beovu (brolucizumab), Faricimab, KSI-301, ADVM022, GB-102, APX3330, THR-149, UBX1325, are expected to have a significant impact on the Diabetic Macular Edema market in the coming years.
Get an overview of pipeline landscape @ Diabetic Macular Edema Clinical Trials Analysis
Diabetic Macular Edema Pipeline Therapies along with Key Players:
-
Beovu (brolucizumab): Novartis
-
Faricimab: Roche
-
KSI-301: Kodiak Sciences
-
ADVM022: Adverum Biotechnologies
-
GB-102: Graybug Vision
-
APX3330: Ocuphire Pharma
-
THR-149: Oxurion
-
UBX1325: Unity Biotechnology
Scope of Diabetic Macular Edema Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Graybug Vision, Ocuphire Pharma, Oxurion, Unity Biotechnology, and others.
-
Pipeline Therapies: Beovu (brolucizumab), Faricimab, KSI-301, ADVM022, GB-102, APX3330, THR-149, UBX1325, and others.
Table of Contents
|
1 |
Diabetic Macular Edema Report Introduction |
|
2 |
Diabetic Macular Edema Executive Summary |
|
3 |
Diabetic Macular Edema Overview |
|
4 |
Diabetic Macular Edema- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Diabetic Macular Edema Pipeline Therapeutics |
|
6 |
Diabetic Macular Edema Late Stage Products (Phase II/III) |
|
7 |
Diabetic Macular Edema Mid Stage Products (Phase II) |
|
8 |
Diabetic Macular Edema Early Stage Products (Phase I) |
|
9 |
Diabetic Macular Edema Preclinical Stage Products |
|
10 |
Diabetic Macular Edema Therapeutics Assessment |
|
11 |
Diabetic Macular Edema Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Diabetic Macular Edema Key Companies |
|
14 |
Diabetic Macular Edema Key Products |
|
15 |
Diabetic Macular Edema Unmet Needs |
|
16 |
Diabetic Macular Edema Market Drivers and Barriers |
|
17 |
Diabetic Macular Edema Future Perspectives and Conclusion |
|
18 |
Diabetic Macular Edema Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Diabetic Macular Edema Drugs Pipeline Report
Related Reports:
DelveInsight’s ‘Diabetic Macular Edema-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Diabetic Macular Edema Epidemiology
DelveInsight’s ‘Diabetic Macular Edema Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Diabetic Macular Edema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/